郑州大学学报(医学版)
鄭州大學學報(醫學版)
정주대학학보(의학판)
JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES)
2014年
6期
805-807
,共3页
CYFRA21-1%膀胱尿路上皮细胞癌
CYFRA21-1%膀胱尿路上皮細胞癌
CYFRA21-1%방광뇨로상피세포암
CYFRA21-1%urothelial bladder carcinoma
目的:检测膀胱尿路上皮细胞癌患者血清中CYFRA21-1水平并探讨其临床意义。方法:采用电化学发光免疫分析技术检测57例膀胱尿路上皮细胞癌患者和52例泌尿系统良性疾病患者以及49例健康个体血清CY-FRA21-1水平。结果:膀胱尿路上皮细胞癌患者血清CYFRA21-1水平和阳性率均高于泌尿系统良性疾病患者与健康人群( F/χ2=28.949、15.221,P均<0.05)。膀胱尿路上皮细胞癌病理分级与血清CYFRA21-1水平及阳性率均无关(P均>0.05)。 T3及T3M+期肿瘤较Ta、T1、T2期肿瘤患者血清CYFRA21-1水平及阳性率均升高(F/χ2=2.096、34.232,P均<0.05);与初发肿瘤相比,复发膀胱尿路上皮细胞癌患者血清CYFRA21-1水平及阳性率均升高(t/χ2=3.968、9.541,P均<0.05)。结论:血清CYFRA21-1可以作为膀胱尿路上皮细胞癌的一个可靠的肿瘤标志物,特别是在监测膀胱尿路上皮癌转移或复发时更具优势。
目的:檢測膀胱尿路上皮細胞癌患者血清中CYFRA21-1水平併探討其臨床意義。方法:採用電化學髮光免疫分析技術檢測57例膀胱尿路上皮細胞癌患者和52例泌尿繫統良性疾病患者以及49例健康箇體血清CY-FRA21-1水平。結果:膀胱尿路上皮細胞癌患者血清CYFRA21-1水平和暘性率均高于泌尿繫統良性疾病患者與健康人群( F/χ2=28.949、15.221,P均<0.05)。膀胱尿路上皮細胞癌病理分級與血清CYFRA21-1水平及暘性率均無關(P均>0.05)。 T3及T3M+期腫瘤較Ta、T1、T2期腫瘤患者血清CYFRA21-1水平及暘性率均升高(F/χ2=2.096、34.232,P均<0.05);與初髮腫瘤相比,複髮膀胱尿路上皮細胞癌患者血清CYFRA21-1水平及暘性率均升高(t/χ2=3.968、9.541,P均<0.05)。結論:血清CYFRA21-1可以作為膀胱尿路上皮細胞癌的一箇可靠的腫瘤標誌物,特彆是在鑑測膀胱尿路上皮癌轉移或複髮時更具優勢。
목적:검측방광뇨로상피세포암환자혈청중CYFRA21-1수평병탐토기림상의의。방법:채용전화학발광면역분석기술검측57례방광뇨로상피세포암환자화52례비뇨계통량성질병환자이급49례건강개체혈청CY-FRA21-1수평。결과:방광뇨로상피세포암환자혈청CYFRA21-1수평화양성솔균고우비뇨계통량성질병환자여건강인군( F/χ2=28.949、15.221,P균<0.05)。방광뇨로상피세포암병리분급여혈청CYFRA21-1수평급양성솔균무관(P균>0.05)。 T3급T3M+기종류교Ta、T1、T2기종류환자혈청CYFRA21-1수평급양성솔균승고(F/χ2=2.096、34.232,P균<0.05);여초발종류상비,복발방광뇨로상피세포암환자혈청CYFRA21-1수평급양성솔균승고(t/χ2=3.968、9.541,P균<0.05)。결론:혈청CYFRA21-1가이작위방광뇨로상피세포암적일개가고적종류표지물,특별시재감측방광뇨로상피암전이혹복발시경구우세。
Aim:To study value of serum CYFRA21-1 in urothelial bladder carcinoma and its clinical significance . Methods:Electrochemiluminescence method was used to detect serum CYFRA 21-1 level of 158 patients, including 57 ca-ses with urothelial bladder carcinoma (group 1), 52 cases with benign diseases of the urinary system (group 2), and 49 healthy individuals(group 3).Results: Compared with group 2 and group 3, serum CYFRA21-1 level and positive rate were significantly higher in group 1 (F/χ2 =28.949,15.221,P<0.05).In group 1, serum CYFRA21-1 levels did not differ significantly among each grade (P>0.05).The CYFRA21-1 level and positive rate increased significantly in T 3 and T3M+stage compared to Ta, T1 and T2 stage(F/χ2 =2.096,34.232,P<0.05).Compared with primary tumor, serum CYFRA21-1 level and positive rate were significantly increased in recurrent urothelial bladder carcinoma ( t/χ2 =3.968, 9.541,P<0.05).Conclusion:Serum CYFRA21-1 seems to be a marker of urothelial bladder carcinoma .It is useful for monitoring this disease , especially for the metastatic and recurrent tumor .